ACTIVE NOT RECRUITING
NCT05180474
GEN1047 for Solid Tumors - First in Human (FIH) Trial
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047:
* The side effects seen with GEN1047
* What the body does with GEN1047 once it is administered
* What GEN1047 does to the body once it is administered
* How well GEN1047 works against solid tumors
The estimated trial duration for an individual participant is 8 months, consisting of a 28-day screening period, an estimated 3 month treatment period (the duration of treatment may vary for each participant), and an estimated 4 month post-treatment follow-up period (the duration of follow-up may vary for each participant). All participants will receive active drug; no one will be given placebo.
Gender: All
Ages: 18 Years - Any
Breast Cancer, Breast Neoplasms
Endometrial Cancer, Endometrial Neoplasm
Ovarian Cancer, Ovarian Neoplasms
+1